Результаты поиска

[Multiple myeloma superimposed on adult T cell lymphoma].

A 77 year-old male was admitted to the hospital because of lumbago and M-proteinemia. IgA (kappa) monoclonal protein (8,100 mg/dl) was demonstrated in serum, and Bence Jones protein (kappa) in urine samples. The bone marrow examination showed an increased number of pathological plasma cells (34. 5%). Multiple osteolytic lesions were evident on X-ray films. A diagnosis of multiple myeloma (MM) was made. He had exudative erythematous skin lesions on his back. His serum was positive for antibody to ATLA. A biopsy specimen from the skin lesions showed Pautrier's micro-abscess which were filled wit…

Multiple myeloma arising from solitary plasmacytoma of bone.

Double (kappa + lambda), Bence Jones (BJ) proteinuria was detected in a male patient of 73 years. The disease started as a solitary plasmacytoma in bone and transformed into multiple myeloma. At the beginning, isolated BJ lambda proteinuria was observed which was soon accompanied by transient excretion of BJ kappa protein.

Autologous bone marrow transplantation therapy for multiple myeloma.

We have begun an autologous bone marrow transplantation (ABMT) treatment protocol for patients with myeloma who achieve a minimal disease (less than 10% marrow plasma cells) status. Sites of bony disease are irradiated before BMT. Melphalan 70 mg/m2 on days 1 and 2 is followed by 1200 rads total-body irradiation administered in fractionated doses over 3 d. Autologous marrow which has been previously treated with anti-CALLA, B1, and PCA-1 monoclonal antibodies is then thawed and reinfused. 4 males and 2 females with median age of 46 yr (41-56) have been treated. Granulocytes greater than 500/mm

Multiple myeloma treated with high dose intravenous melphalan.

High dose melphalan (HDM, 140 mg/m2 i.v.) has been evaluated in 58 patients under 63 years with multiple myeloma. Among previously untreated patients 11/41 (27%) entered a complete remission (CR: no measurable myeloma protein and a normal bone marrow) and 21 (51%) entered a partial remission (more than 50% reduction in myeloma protein and improvement in all other features). Median duration of remission is 19 months. Two patients who had responded to previous conventional treatment entered CR after HDM. Among 15 patients who had failed on previous chemotherapy the response rate was 66% includin…

[Lichen myxedematosus and multiple myeloma type IgG/kappa].

Lichen myxedematosus and scleromyxedema are rare disorders with cutaneous deposition of mucin, without any disturbance of the thyroid function. They are regularly associated with the presence of abnormal proteins in the serum. These proteins have been now identified as paraproteins and are one of the main symptoms of these diseases. The association of a papular mucinosis with a classical plasmacytoma is exceptional. We report a patient in whom lichen myxedematosus is associated with a multiple myeloma of the type IgG/kappa. Cultured skin fibroblasts show a marked decrease of arylsulfatase A ac…

Sequential hemi-body radiotherapy in advanced multiple myeloma.

Eleven patients with advanced multiple myeloma refractory to standard chemotherapy were treated with a regimen of sequential hemi-body radiotherapy consisting of 800 rad midplane in a single dose to each half. 9/10 patients experienced significant relief of skeletal pain and there were 5/11 objective tumor responses with one complete remission. Treatment-related morbidity was significant and consisted primarily of nausea and emesis, bone marrow suppression, and pneumonitis. This therapy is helpful in the management of advanced myeloma, and should be studied earlier in the course of the disease…

Functional characterization of neutrophils in patients with multiple myeloma.

Multiple myeloma is a hematologic cancer caused by abnormal plasma cell proliferation in the bone marrow and is associated with significant immune dysfunction. Neutrophils, essential components of the innate immune response, may function poorly in patients with multiple myeloma, increasing the risk of infection and affecting disease progression. This study aimed to systematically evaluate the extent of neutrophil dysfunction in patients with newly diagnosed and relapsed multiple myeloma. The study employed a cross-sectional analytical design and recruited 72 participants: 30 multiple myeloma p…

Bortezomib-Induced Myocarditis in a Patient With Multiple Myeloma.

BACKGROUND: Bortezomib is a reversible proteasome inhibitor used as first-line therapy for multiple myeloma and mantle cell lymphoma. Although effective, it can in rare cases cause cardiotoxicity, including myocarditis. CASE SUMMARY: A 58-year-old man with multiple myeloma (MC I, lambda light chain type) developed progressive dyspnea and edema after VTD (bortezomib, thalidomide, dexamethasone) therapy. Echocardiography showed severe left ventricular systolic dysfunction (left ventricular ejection fraction: 35%, global longitudinal strain: -10%) with elevated troponin I (3,176 ng/L). Coronary …

Прогресс в патофизиологии и лечении анемии в множестве миеломы.

ЦЕЛЬ РАССМОТРЕНИЯ: Анемия является общим признаком во многих миеломах благодаря многофакторным механизмам. Помимо хорошо известных факторов, связанных с этим заболеванием, в последнее время использование ряда новых лекарственных средств в качестве иммунотерапевтических указывает на формирующуюся роль связанных с наркотиками механизмов в патофизиологии анемии у многих пациентов, страдающих миеломой. ПОСЛЕДНИЕ ФИННДИНЫ: Анемия, связанная с иммуномодулятивными препаратами, может быть вызвана как непосредственным воздействием на гематопоиетические клетки потомства, так и косвенным воздействием one

Совпадение в аннотации оригинала
PURPOSE OF REVIEW: Anaemia is a common sign in multiple myeloma due to multifactorial mechanisms. Apart from the well known factors related to the disease, more recently, the use of several new drugs as the immunotherapeutic ones indicates the emerging role of drug-related mechanisms in the pathophysiology of anaemia in multiple myeloma patients. RECENT FIN…

Toward a cure for multiple myeloma within a decade.

Multiple myeloma (MM), long viewed as incurable, is entering a transformative era marked by deeper remissions, prolonged survival, and the realistic prospect of cure. The greatest opportunity lies at diagnosis, before genomic heterogeneity and immune escape limit therapeutic impact. High-risk smoldering MM provides a preclinical window where early intervention with targeted antibodies or combinations can delay progression and, as in some trials, improve survival. Refining the threshold for treatment-entry requires integrated risk models that combine genomics, microenvironmental and immune prof…

Отталкиваю меняющееся управление хмурящейся множественной миеломой.

Множественная миелома (SMM) представляет собой промежуточную клиническую стадию между моноклонной гаммопатией неопределенного значения (MMUS) и симптоматической множественной миеломой (MM). ШМ сопряжена с весьма изменчивым риском перехода к ММ, что требует индивидуальной стратификации рисков для руководства управлением. Исторически модели риска основывались на статических клинических маркерах, отражающих бремя опухоли, для прогнозирования прогресса. Несмотря на свою полезность, эти модели не смогли зафиксировать лежащую в основе этого заболевания биологическую неоднородность. Последние достиже…

Эволюция множественной миеломы с геномной точки зрения.

В настоящем обзоре мы изучаем роль сложных взаимосвязей между геномной эволюцией, экологической и генетической предрасположенностью и иммунным слежением в прогрессии заболеваний в условиях, связанных с прекурсором, затухающим множественным миеломой и моноклональной гаммопатией неопределённого значения для множественной миеломы (ММ). ММ описывается как универсальное явление, которому предшествуют государства-прекурсоры, зачастую за несколько десятилетий до того, как его диагностируют. Генетическая предрасположенность играет важную роль в первоначальном преобразовании, и ее движущей силой являют…

Множественная миелома: сказка о дерегулированных факторах транскрипции.

Всеобъемлющее понимание молекулярных механизмов, лежащих в основе множественных миэломных (ММ) патогенеза, крайне важно для разработки терапевтических стратегий, позволяющих преодолеть гетерогенность заболеваний и рецидив лечения. В этом обзоре мы сосредоточимся на коэффициентах транскрипции (TF), ключевых регуляторах генного экспрессия, которые играют важнейшую роль в обычной гематопоизисе и биологии MM. Сначала мы обсудим физиологические функции ТФ в составе лимфоидной линии и конечной дифференциации В-клеток на плазменные клетки. Это позволяет получить представление о вкладе ключевых ЦГ, та

Совпадение в аннотации оригинала
A comprehensive understanding of the molecular mechanisms underlying multiple myeloma (MM) pathogenesis is essential for developing therapeutic strategies that overcome disease heterogeneity and treatment relapse. In this review, we focus on transcription factors (TFs), key regulators of gene expression that play critical roles in normal hematopoiesis and MM…

Практическое управление биконкретными антителами в Мультимиломе.

Площадь для лечения повторной/редактируемой множественной миэломы была изменена в результате одобрения T-перенаправляющих биэлементов антите … еспечения справедливого доступа и максимального увеличения долгосрочных результатов для пациентов с множественной миеломой.

[Research progress on mitochondrial dysfunction in multiple myeloma].

Multiple myeloma ranks as the second most prevalent hematological malignancy. It remains incurable and is characterized by frequent drug resistance and disease relapse. Mitochondria, as a key hub for cellular energy metabolism and homeostasis regulation, have been found to have functional abnormalities in various cancers. The occurrence, progression and drug resistance of multiple myeloma are also closely linked to mitochondrial dysfunction. Existing research has shown that multiple myeloma cells acquire survival advantages and escape therapeutic elimination by enhancing oxidative phosphorylat…

Dynamic Prediction of Survival Outcomes in Multiple Myeloma.

Background: Multiple myeloma (MM) remains an incurable plasma cell malignancy characterized by marked clinical heterogeneity. Existing prognostic frameworks, including the International Staging System (ISS) and FISH-defined cytogenetic risk, are anchored at diagnosis and do not capture the evolutionary dynamics of disease or treatment response, leaving an unmet need for risk models that retain prognostic validity longitudinally. Methods: Using transcriptomic data from 762 CD138-selected MM plasma cells from newly diagnosed patient samples in the MMRF CoMMpass study (NCT01454297), we computed s…

Cutaneous involvement in multiple myeloma. A rare entity.

Cutaneous involvement in multiple myeloma is rare and may present as nodules mimicking other lymphoid neoplasms. It typically occurs late in the course of the disease and is associated with an aggressive clinical course and poor prognosis.